We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

112 hedge funds and large institutions have $215M invested in Arbutus Biopharma in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 34 increasing their positions, 29 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 7

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

49% more capital invested

Capital invested by funds: $144M → $215M (+$71M)

18% more call options, than puts

Call options by funds: $4.66M | Put options by funds: $3.94M

17% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 29

13% more funds holding

Funds holding: 99 → 112 (+13)

8.96% more ownership

Funds ownership: 42.28% → 51.24% (+9%)

Holders
112
Holders Change
+13
Holders Change %
+13.13%
% of All Funds
1.63%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
21
Increased
34
Reduced
29
Closed
7
Calls
$4.66M
Puts
$3.94M
Net Calls
+$718K
Net Calls Change
+$63K

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$17.1M
2
WCM
Whitefort Capital Management
New York
+$2.55M
3
TSC
Two Seas Capital
New York
+$1.49M
4
CC
Centiva Capital
New York
+$684K
5
State Street
State Street
Massachusetts
+$461K

Top Sellers

1
JFG
Jefferies Financial Group
New York
-$537K
2
FCM
FourWorld Capital Management
New York
-$492K
3
KC
Kepos Capital
New York
-$316K
4
Citigroup
Citigroup
New York
-$230K
5
Ameriprise
Ameriprise
Minnesota
-$199K
Name Holding Trade Value Shares
Change 		Change in
Stake
HIA
101
Harbor Investment Advisory
Maryland
$2.01K – – –
FDCDDQ
102
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2K – – –
PA
103
Parallel Advisors
California
$1.38K – – –
BBPWM
104
Blue Bell Private Wealth Management
Pennsylvania
$1.25K – – –
Daiwa Securities Group
105
Daiwa Securities Group
Japan
$1K – – –
HFS
106
Hantz Financial Services
Michigan
$1K – – –
LC
107
Lindbrook Capital
California
$710 +$556 +284 New
QCG
108
Quadrant Capital Group
Ohio
$693 -$1.24K -635 -70%
PWMG
109
Private Wealth Management Group
New Jersey
$605 +$474 +242 New
PNC Financial Services Group
110
PNC Financial Services Group
Pennsylvania
$520 +$407 +208 New
GI
111
GAMMA Investing
California
$443 +$366 +187 New
JFG
112
Jefferies Financial Group
New York
– -$537K -264,441 Closed
KC
113
Kepos Capital
New York
– -$316K -155,691 Closed
Ameriprise
114
Ameriprise
Minnesota
– -$199K -98,000 Closed
AQR Capital Management
115
AQR Capital Management
Connecticut
– -$82.4K -40,598 Closed
VEA
116
Virtus ETF Advisers
New York
– -$81.3K -40,040 Closed
Victory Capital Management
117
Victory Capital Management
Texas
– -$28K -13,810 Closed
US Bancorp
118
US Bancorp
Minnesota
– -$3.88K -1,909 Closed
Carson Wealth (CWM LLC)
119
Carson Wealth (CWM LLC)
Nebraska
– +$260 +133 +1,330%
1 2 3 4
5

ABUS Hedge Fund Activity: Q4 2023 in Review

112 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2023, worth a combined $215M — up 49% from $144M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new ABUS positions and 7 closed out — a net gain of 14 holders — while 34 added to existing stakes and 29 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $17.1M. The largest seller was Jefferies Financial Group, exiting entirely with an estimated $537K sold.

  • 112 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2023, up from 99 in Q3 2023.
  • Funds reported $215M of Arbutus Biopharma stock for Q4 2023, up 49% quarter-over-quarter.
  • 21 funds opened new Arbutus Biopharma positions in Q4 2023 and 7 closed out, a net change of +14 holders.
  • The largest Arbutus Biopharma buyer in Q4 2023 was Morgan Stanley, an estimated $17.1M added.
  • The largest Arbutus Biopharma seller in Q4 2023 was Jefferies Financial Group, an estimated $537K sold.

Based on aggregated 13F filings for Q4 2023.